omniture
logo
Search
上海璎黎药业有限公司 Shanghai Maya Li Pharmaceutical Co. Ltd
Media Room

Latest News

rss

Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting

Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable s...

2023-12-11 21:00 1514

280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ -- 280Bio, Inc., a clinical stage biotechnol...

2023-12-01 21:00 1467

280 Bio receives IND approval from the FDA for YL-17231

---The Company announces to initiate Phase 1 Clinical Trial with the KRAS inhibitor YL-17231 in US-...

2023-07-07 20:00 2823

280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting

A broadly acting KRAS Inhibitor, TEB-17231, robustly blocks tumor growth and overcomes KRASG12C inh...

2023-03-21 20:00 1561

Yingli Pharma Announces a presentation on the Phase 2 clinical trial of linperlisib, a PI3Kδ selective inhibitor, in relapsed or refractory follicular lymphoma at the European Hematology Association 2021 Congress

SHANGHAI, June 11, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clin...

2021-06-11 13:05 2356

Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting

Clinical trial data will be updated in three presentations on lead drug candidates * Linperlisib...

2021-06-04 14:29 2317

Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib

* Linperlisib provides significant clinical improvement in the treatment for patients with relapse...

2021-04-01 14:09 1480

Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China

SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Yingli Pharma announced today that it reached strategic coll...

2021-02-09 08:30 1798